Baker McKenzie Baker McKenzie
How Can We Help?
  • Home
  • Expertise
  • Life Sciences Transactions

Life Sciences Transactions

Insight | Thought Leadership

Life Sciences Business Evolution Series: Funding Growth and the Future of Life Sciences

Life sciences companies intend to leverage new and existing sources of growth including through M&A, carve-outs, divestitures, partnerships, licensing and collaboration agreements as well as avenues tied to corporate PPAs and green financing. Find out about these trajectories as well as continued VC investment and increasing appetite from private equity sponsors in pre-revenue stages.
Read More

Navigating the ever-changing market reality requires responding to growing competition whilst managing cost pressures all while trying to achieve sustainable growth. Get well-rounded advice across 46 jurisdictions from a life sciences transactions team with a keen view of the transactional landscape, industry trends and regulatory outlook.

Explore more below.

Collaborations and Licensing

expand accordion
  • Complex multinational collaborations
  • Joint ventures
  • Commercialization agreements
  • Co-promotion agreements
  • Research and development agreements
  • Evaluation and option agreements

M&A

expand accordion
  • Product acquisitions and divestitures
  • Company sales and acquisitions
  • Business unit spinoffs
  • Post-acquisition integration

Financings

expand accordion
  • Equity financing
  • Royalty monetization
  • Development funding agreements

Operational Agreements

expand accordion
  • Manufacturing and supply agreements
  • Distribution agreements
  • Services agreements
  • University and other nonprofit agreements
Insight | Handbook
Guide to IPOs for Biotech and Pharma Companies
Biotech and pharma companies undertaking capital raisings can approach the world’s capital markets in various ways.
Insight | Podcast
The Health Pod
The Health Pod, Baker McKenzie's industry podcast series, highlights sector-specific issues and trends that affect healthcare and life sciences companies.
Insight | Handbook
2022 Chambers Advertising & Marketing Practice Guide
This guide provides the latest legal information on comparative advertising, social/digital media, influencer campaigns, cryptocurrency, non-fungible tokens (NFTs) and others.
Insight | Thought Leadership
Data PULSE
Our Data PULSE platform helps you navigate the complex landscape of data, regulatory and IP protection concerns at each stage of the medical product life cycle.
Insight | Handbook
New Chambers Life Sciences Practice Guide 2022
As the global editor, we introduce this year's guide offering commentary on a wide range of legal and business issues in major healthcare and life sciences markets.
Insight | Thought Leadership
Life Sciences Business Evolution Series
Explore how pharma biotech, medical devices and medtech companies plan to evolve their business models, shaping the future of the life sciences ecosystem.
Insight | Thought Leadership
More Aggressive Scrutiny of Life Science Deals - But Is There a Problem That Needs Solving?
Fiona Carlin, Anthony Gamble, Dan Graulich and Yana Ermak consider the justifications for this tougher approach and explore the potential chilling effect it might have.
Insight | Legal Update
Foreign Investment Screening and Healthcare
What are the implications of the new NSI Act regime and the Government's "public health emergencies" powers for healthcare and life sciences transactions?
Insight | Thought Leadership
The Future of Capital Raising in Biotech and Pharma
Despite a decline in overall global activity, the biopharma sectors continue to perform strongly, bolstered by several factors. 
Insight | Recorded Webinar
Healthcare & Life Sciences Supply Chain Series
The Supply Chain Series focuses on the trends, issues and opportunities along each stage of supply chain life cycle for healthcare and life sciences companies.
Insight | Recorded Webinar
Masterclass: Partnering & Licensing
At the LSX Investival Showcase, our lawyers share insights on how biotech companies can navigate licensing issues.  
View All Insight
News | Deal Announcement
Baker McKenzie Advises Abbott Laboratories in $890 Million Acquisition
Baker McKenzie advised Abbott Laboratories in its acquisition of Cardiovascular Systems, Inc. in an all-cash transaction valued at approximately $890 million.
News | Deal Announcement
Baker McKenzie Advises Wilbur-Ellis in Merger to Form Leading Global Life Sciences and Specialty Chemicals Solutions Distribution Platform with Combined Sales of Approximately EUR 3 Billion
The deal will create a global leader in the life sciences and specialty chemicals solutions sector.
News | Deal Announcement
Baker McKenzie Advised Bristol Myers Squibb in Strategic Collaboration with Amphista Therapeutics
Firm advised Bristol Myers Squibb in a strategic collaboration and license agreement with Amphista.
News | Deal Announcement
Mithra Obtains Equity Funding for up to EUR 100 Million
The arrangement has been entered into for a term of approximately 2 years.
News
Baker McKenzie Interview with Bayer AG Head of Legal M&A Featured in Corporate Counsel
Baker McKenzie Partners Alan Zoccolillo and Piotr Korzynski spoke with Deny-Jean Silny, Bayer AG's Head of Legal M&A, about his transition to his current role.
News | Deal Announcement
Baker McKenzie advises BNP Paribas and Deutsche Bank on CHF 19 billion bridge financing for Roche
Baker McKenzie acted for BNP Paribas and Deutsche Bank in connection with their approximately CHF 19 billion bridge facility for Roche Holding Ltd.
View All News

How We Can Help

Key Resources

Life sciences

Life Sciences Collaborations: Key Considerations in the COVID-19 Era

A high-level guide that outlines a list of issues to consider in executing life sciences collaborations in the COVID-19 era
Asia Pacific Dealscape

Asia Pacific DealSCAPE

Explore the defining characteristics of transactions using the SCAPE framework and understand legal complexity and stress test plans in an evolving landscape

FT Big Deal Series: The Healthtech Sector’s Spectacular Surge in SPACs and de-SPACS

A three minute video discussing how the pandemic triggered a significant rise in SPAC investments in the healthtech sector.


Flares of different colored light against a black background

Guide to IPOs for Biotech and Pharma Companies

Biotech and pharma companies undertaking capital raisings can approach the world’s capital markets in various ways.


The Health Pod

Baker McKenzie's industry podcast series that highlights sector-specific issues and trends that affect healthcare & life sciences companies.

About Us

Learn about our Global Healthcare & Life Sciences Industry Group in 5 minutes

Key Contacts